dc.contributor.author | Denis-Bacelar, AM | |
dc.contributor.author | Chittenden, SJ | |
dc.contributor.author | Dearnaley, DP | |
dc.contributor.author | Divoli, A | |
dc.contributor.author | O'Sullivan, JM | |
dc.contributor.author | McCready, VR | |
dc.contributor.author | Johnson, B | |
dc.contributor.author | Du, Y | |
dc.contributor.author | Flux, GD | |
dc.date.accessioned | 2016-11-14T16:54:59Z | |
dc.date.issued | 2017-04 | |
dc.identifier.citation | European journal of nuclear medicine and molecular imaging, 2017, 44 (4), pp. 620 - 629 | |
dc.identifier.issn | 1619-7070 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/206 | |
dc.identifier.eissn | 1619-7089 | |
dc.identifier.doi | 10.1007/s00259-016-3543-x | |
dc.description.abstract | Purpose To investigate the role of patient-specific dosimetry as a predictive marker of survival and as a potential tool for individualised molecular radiotherapy treatment planning of bone metastases from castration-resistant prostate cancer, and to assess whether higher administered levels of activity are associated with a survival benefit.Methods Clinical data from 57 patients who received 2.5-5.1 GBq of 186 Re-HEDP as part of NIH-funded phase I/II clinical trials were analysed. Whole-body and SPECT-based absorbed doses to the whole body and bone lesions were calculated for 22 patients receiving 5 GBq. The patient mean absorbed dose was defined as the mean of all bone lesion-absorbed doses in any given patient. Kaplan-Meier curves, log-rank tests, Cox's proportional hazards model and Pearson's correlation coefficients were used for overall survival (OS) and correlation analyses.Results A statistically significantly longer OS was associated with administered activities above 3.5 GBq in the 57 patients (20.1 vs 7.1 months, hazard ratio: 0.39, 95 % CI: 0.10-0.58, P = 0.002). A total of 379 bone lesions were identified in 22 patients. The mean of the patient mean absorbed dose was 19 (±6) Gy and the mean of the whole-body absorbed dose was 0.33 (±0.11) Gy for the 22 patients. The patient mean absorbed dose (r = 0.65, P = 0.001) and the whole-body absorbed dose (r = 0.63, P = 0.002) showed a positive correlation with disease volume. Significant differences in OS were observed for the univariate group analyses according to disease volume as measured from SPECT imaging of 186 Re-HEDP (P = 0.03) and patient mean absorbed dose (P = 0.01), whilst only the disease volume remained significant in a multivariable analysis (P = 0.004).Conclusion This study demonstrated that higher administered activities led to prolonged survival and that for a fixed administered activity, the whole-body and patient mean absorbed doses correlated with the extent of disease, which, in turn, correlated with survival. This study shows the importance of patient stratification to establish absorbed dose-response correlations and indicates the potential to individualise treatment of bone metastases with radiopharmaceuticals according to patient-specific imaging and dosimetry. | |
dc.format | Print-Electronic | |
dc.format.extent | 620 - 629 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Bone Neoplasms | |
dc.subject | Organometallic Compounds | |
dc.subject | Etidronic Acid | |
dc.subject | Radiopharmaceuticals | |
dc.subject | Tomography, Emission-Computed, Single-Photon | |
dc.subject | Radiotherapy Dosage | |
dc.subject | Radiotherapy Planning, Computer-Assisted | |
dc.subject | Survival Analysis | |
dc.subject | Radiation Dosage | |
dc.subject | Male | |
dc.subject | Clinical Trials, Phase I as Topic | |
dc.subject | Clinical Trials, Phase II as Topic | |
dc.subject | Prostatic Neoplasms, Castration-Resistant | |
dc.title | Phase I/II trials of <sup>186</sup>Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-09-30 | |
rioxxterms.versionofrecord | 10.1007/s00259-016-3543-x | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2017-04 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European journal of nuclear medicine and molecular imaging | |
pubs.issue | 4 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 44 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Clinical Academic Radiotherapy (Dearnaley) | en_US |
icr.researchteam | Radioisotope Physics | en_US |
dc.contributor.icrauthor | Denis-Bacelar, Ana | en |
dc.contributor.icrauthor | Dearnaley, David | en |
dc.contributor.icrauthor | Flux, Glenn | en |
dc.contributor.icrauthor | Marsden, | en |